Baylor Genetics Deploys New Tech to Solve Rare Disease Mysteries

HOUSTON, TX – March 10, 2026 – Baylor Genetics today announced a significant enhancement to its clinical arsenal against rare and undiagnosed diseases, integrating advanced technologies into its flagship Whole Genome Sequencing (WGS) test. The move aims to provide a much deeper and more precise view of a patient’s DNA, potentially solving medical mysteries that have stumped clinicians for years.

The Houston-based company will now supplement its WGS with optical genome mapping (OGM) and long-read sequencing (LRS), two powerful methods designed to overcome the inherent limitations of standard genomic tests. These technologies, along with RNA sequencing, will be automatically used for eligible cases, creating a multi-layered diagnostic approach intended to find answers for the most complex patients.

A New Multimodal Approach to Genomics

For years, Whole Genome Sequencing has been a revolutionary tool, capable of reading a person’s entire genetic code. However, the standard method, known as short-read sequencing, is akin to reassembling a shredded encyclopedia using only small, confetti-sized pieces of paper. While effective for spotting small typos—or single nucleotide variants—it struggles to identify when entire pages or chapters are rearranged, inverted, or duplicated.

This is where the new supplemental technologies come in. Optical Genome Mapping (OGM) provides a high-level blueprint of the genome. It analyzes extremely long DNA molecules, creating a unique barcode-like pattern that makes large structural changes, such as inversions or translocations of entire gene segments, glaringly obvious. It offers a genome-wide view that can detect major architectural flaws missed by other methods.

Long-Read Sequencing (LRS), meanwhile, tackles the problem from a different angle. By reading much longer continuous segments of DNA, it can successfully navigate the genome's most challenging terrain: long, repetitive regions. These genetic stutters, known as short tandem repeats (STRs), are notoriously difficult for short-read methods to accurately count. Pathogenic expansions of these STRs are the known cause of dozens of severe neurological and neuromuscular disorders. With LRS, Baylor Genetics will more than double its coverage for these conditions, expanding its analysis from 29 to 58 genes associated with STRs.

Furthermore, certain LRS platforms can directly detect methylation—a chemical tag on DNA that controls gene activity—without extra processing. This is a critical upgrade for diagnosing conditions like Fragile X syndrome, where the silencing of the FMR1 gene through methylation is the definitive pathogenic event. The new test will now incorporate this analysis, combining repeat counting and methylation status into a single, streamlined workflow.

Ending the 'Diagnostic Odyssey' for Patients

The ultimate goal of this technological fusion is to shorten the painful and costly “diagnostic odyssey” that countless families endure. Standard WGS currently provides a definitive diagnosis in about 25-40% of rare disease cases. While a remarkable figure, it leaves the majority of patients and their doctors without answers, often leading to years of uncertainty, repeated testing, and ineffective treatments.

By integrating OGM and LRS, the company aims to significantly increase that diagnostic yield. The enhancements are specifically targeted at patients with the most challenging presentations: those with unresolved clinical features despite previous testing, individuals with progressive neurologic symptoms, and those with clinical signs pointing to conditions like Fragile X syndrome.

“While genomic sequencing is increasingly the standard of care for patients with rare disease, too many patients still complete testing without receiving the answers they need,” said Dr. Christine Eng, Chief Medical Officer and Chief Quality Officer at Baylor Genetics, in the company’s announcement. “At Baylor Genetics, we believe that more answers are possible. Our multimodal approach to testing is designed to uncover deeper insights that meaningfully guide patient care.”

For these patients, a diagnosis can be life-altering. It can provide access to targeted therapies, guide medical management, inform family planning, and connect families with support networks. Perhaps most importantly, it can provide the profound relief of simply having a name for what has long been a medical mystery.

Reshaping the Competitive Landscape

Baylor Genetics' decision to formally integrate OGM and LRS into its clinical WGS workflow positions it as a leader in a rapidly evolving diagnostics market. While many academic centers have been using these technologies in research for years, their transition into a routine, reflexed clinical offering by a major commercial lab marks a significant milestone.

The move reflects a broader industry trend away from a one-size-fits-all approach to genomics. Leading experts believe the future of diagnostics lies in combining multiple data types—or a “multi-omics” approach—to build a comprehensive biological picture. By creating a pipeline that seamlessly combines short-read WGS, OGM, LRS, and functional RNA analysis, Baylor is making a strategic bet that the most complete picture will provide the most value to clinicians and patients.

This positions the company to attract complex cases that have failed to receive a diagnosis elsewhere, potentially establishing it as a premier destination for refractory diagnostic challenges. The emphasis on expert interpretation and genetic counseling support is also a key differentiator, as the complexity of the data generated by these platforms makes human expertise more critical than ever.

The Hurdles of Access and Reimbursement

Despite the clear scientific and clinical advantages, the path to widespread patient access is not without obstacles, primarily centering on cost and insurance reimbursement. Advanced genomic tests are expensive, and convincing payers of their value is an ongoing battle across the industry.

However, there are signs of progress. In a significant step forward, a new Category I CPT code—the standard for medical billing—was recently established for optical genome mapping. This provides a clearer pathway for labs to bill for the service, though it does not guarantee payment. Each insurance provider, whether public or private, will still make its own coverage decisions based on its assessment of medical necessity and clinical utility.

Advocates argue that while the upfront cost of these tests is high, they can ultimately save the healthcare system money by preventing years of inconclusive tests, misdiagnoses, and ineffective treatments. The ability to deliver a swift, definitive diagnosis can streamline care and improve outcomes, providing a powerful health economic argument.

As the technologies mature and costs continue to fall, and as more clinical data demonstrates their impact on diagnostic yield, reimbursement policies are expected to become more favorable. Baylor Genetics' move to offer these tests as an automated reflex for certain cases suggests confidence that it can navigate the current reimbursement landscape and a belief that this comprehensive approach will soon become the undisputed standard of care for complex genetic disease.